Update on nitazoxanide: A multifunctional chemotherapeutic agent

Current Drug Discovery Technologies

Volumn 15, Issue 3, 2018, Pages 201-213

  Shakya, Anshul ^a   Bhat, Hans Raj ^a   Ghosh, Surajit Kumar ^a  

^a DIBRUGARH UNIVERSITY   (India)

Author keywords

Anthelminthic; Antibacterial; Anticancer; Antiprotozoal; Antiviral; Thiazolide

Indexed keywords

ALPHA TYPE SUBUNIT GLUTAMATE GATED CHLORIDE ION CHANNEL; ANNITA; CHAPERONE; CHLORIDE CHANNEL; DEXIDEX; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE P1; IMMEDIATE EARLY PROTEIN; INITIATION FACTOR; KIDONAX; NAD(P)H DEHYDROGENASE(QUINONE 1); NITAZOXANIDE; NITROREDUCTASE; NITROREDUCTASE 1; OXIDOREDUCTASE; PARAMIX; PROTEIN DISULFIDE ISOMERASE; PYRUVATE DEHYDROGENASE; PYRUVATE FLAVODOXIN OXIDOREDUCTASE; PYRUVATE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TRANSCRIPTION FACTOR IMMEDIATE EARLY 2; TRANSLATION INITIATION FACTOR 2ALPHA; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; THIAZOLE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMEBIASIS; ANAEROBIC BACTERIUM; ANTHELMINTIC ACTIVITY; ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROTOZOAL ACTIVITY; ANTIVIRAL ACTIVITY; APICOMPLEXAN INFECTION; ASCARIASIS; AUTOPHAGY; BLASTOCYSTOSIS; BREAST CANCER; CELL MEMBRANE; CESTODIASIS; CHAGAS DISEASE; CHIKUNGUNYA; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; COLITIS; COLORECTAL CANCER; CRYPTOSPORIDIOSIS; CYSTICERCOSIS; CYTOMEGALOVIRUS INFECTION; DENGUE; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ECHINOCOCCOSIS; ELEPHANTIASIS; ENCEPHALITIS; ENERGY METABOLISM; ENTERITIS; ENTEROBIASIS; ENZYME INHIBITION; EQUINE PROTOZOAL MYELOENCEPHALITIS; ESCHERICHIA COLI; FASCIOLIASIS; FOOD POISONING; GASTRITIS; GASTROENTERITIS; GIARDIASIS; GLUCOSE METABOLISM; GRAM NEGATIVE BACTERIUM; HEPATITIS; HOMEOSTASIS; HOOKWORM INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYMENOLEPIASIS; IMMUNOMODULATION; INFLUENZA; ISOSPORIASIS; JAPANESE ENCEPHALITIS; LEISHMANIASIS; LYMPHATIC FILARIASIS; MACROPHAGE; MALARIA; MEMBRANE DEPOLARIZATION; MEMBRANE POTENTIAL; MIDDLE EAST RESPIRATORY SYNDROME; MITOCHONDRIAL MEMBRANE; MOLECULAR INTERACTION; MYCOBACTERIUM TUBERCULOSIS; NEMATODE; NEMATODIASIS; NEOSPOROSIS; NEUROCYSTICERCOSIS; NONHUMAN; ONCOGENE C MYC; OVARY CARCINOMA; PH; RESPIRATORY TRACT INFECTION; REVIEW; SARCOCYSTOSIS; STOMACH ULCER; STRONGYLOIDIASIS; TAENIASIS; TOXOCARIASIS; TOXOPLASMOSIS; TRICHINOSIS; TRICHOMONIASIS; TRICHURIASIS; TRYPANOSOMIASIS; TUBERCULOSIS; TUMOR CELL; TUMOR GROWTH; UNFOLDED PROTEIN RESPONSE; VIRAL GASTROENTERITIS; VIRUS REPLICATION; YELLOW FEVER; ANIMAL;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; HUMANS; THIAZOLES;

EID: 85049589477     PISSN: 15701638     EISSN: 18756220     Source Type: Journal    
DOI: 10.2174/1570163814666170727130003     Document Type: Review

References (203)

1. Rossignol JF, Maisonneuve H. Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana infections. Am J Trop Med Hyg 1984; 33: 511-2.
2. Hemphill A, Mueller J, Esposito M. Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections. Expert Opin Pharmacother 2006; 7: 953-64.
3. Ballard TE, Wang X, Olekhnovich I, et al. Synthesis and antimicrobial evaluation of nitazoxanide-based analogues: Identification of selective and broad spectrum activity. Chem Med Chem 2011; 6: 362-77.
4. Hof H, Stroder J, Buisson JP, Royer R. Effect of different nitroheterocyclic compounds on aerobic, microaerophilic, and anaerobic bacteria. Antimicrob Agents Chemother 1986; 30: 679-83.
5. Bobak DA. Use of nitazoxanide for gastrointestinal tract infections: Treatment of protozoan parasitic infection and beyond. Curr Infect Dis Rep 2006; 8: 91-5.
6. Wright SG. Protozoan infections of the gastrointestinal tract. Infect Dis Clin North Am 2012; 26: 323-39.
7. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: A randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 2001; 184: 381-4.
8. Fox LM, Saravolatz LD. Nitazoxanide: A new thiazolide antiparasitic agent. Clin Infect Dis 2005; 40: 1173-80.
9. Parashar A, Arya R. Nitazoxanide. Indian Pediatr 2005; 42: 1161-5.
10. Stachulski AV, Swift K, Cooper M, et al. Synthesis and preclinical studies of new amino acid ester thiazolide prodrugs. Eur J Med Chem 2017; 126: 154-9.
11. Hoffman PS, Sisson G, Croxen MA, et al. Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni. Antimicrob Agents Chemother 2007; 51: 868-76.
12. Ballard TE, Wang X, Olekhnovich I, et al. Biological activity of modified and exchanged 2-amino-5-nitrothiazole amide analogues of nitazoxanide. Bioorg Med Chem Lett 2010; 20: 3537-9.
13. Aslam S, Musher DM. Nitazoxanide: Clinical studies of a broadspectrum anti-infective agent. Future Microbiol 2007; 2: 583-90.
14. Anderson VR, Curran MP. Nitazoxanide: A review of its use in the treatment of gastrointestinal infections. Drugs 2007; 67: 1947-67.
15. Hotez PJ. Could Nitazoxanide be added to other essential medicines for integrated neglected tropical disease control and elimination? PLoS Negl Trop Dis 2014; 8: e2758.
16. Navarrete-Vazquez G, Chavez-Silva F, Argotte-Ramos R, et al. Synthesis of benzologues of Nitazoxanide and Tizoxanide: A comparative study of their in vitro broad-spectrum antiprotozoal activity. Bioorg Med Chem Lett 2011; 21: 3168-71.
17. Chan-Bacab MJ, Hernandez-Nunez E, Navarrete-Vazquez G. Nitazoxanide, tizoxanide and a new analogue [4-nitro-N-(5-nitro-1,3-thiazol-2-yl)benzamide; NTB] inhibit the growth of kinetoplastid parasites (Trypanosoma cruzi and Leishmania mexicana) in vitro. J Antimicrob Chemother 2009; 63: 1292-3.
18. Nava-Zuazo C, Chavez-Silva F, Moo-Puc R, et al. 2-Acylamino-5-nitro-1,3-thiazoles: Preparation and in vitro bioevaluation against four neglected protozoan parasites. Bioorg Med Chem 2014; 22: 1626-33.
19. Muller J, Rout S, Leitsch D, Vaithilingam J, Hehl A, Muller N. Comparative characterisation of two nitroreductases from Giardia lamblia as potential activators of nitro compounds. Int J Parasitol Drugs Drug Resist 2015; 5: 37-43.
20. Moron-Soto M, Gutierrez L, Sumano H, Tapia G, Alcala-Canto Y. Efficacy of nitazoxanide to treat natural Giardia infections in dogs. Parasit Vectors 2017; 10: 52.
21. Silva-Diaz H, Flores-Esqueche L, Llatas-Cancino D, Guevara Vasquez G, Silva-Garcia T. Frequency and in vitro susceptibility antiparasitic of Blastocystis hominis from patients admitted to the Hospital Regional Lambayeque, Peru. Rev Gastroenterol Peru 2016; 36: 197-202.
22. Manjunatha UH, Chao AT, Leong FJ, Diagana TT. Cryptosporidiosis drug discovery: Opportunities and challenges. ACS Infect Dis 2016; 2: 530-7.
23. Speich B, Marti H, Ame SM, et al. Prevalence of intestinal protozoa infection among school-aged children on Pemba Island, Tanzania, and effect of single-dose albendazole, nitazoxanide and albendazolenitazoxanide. Parasit Vectors 2013; 6: 3.
24. Asai T, Cordova Vidal C, Strauss W, Ikoma T, Endoh K, Yamamoto M. Effect of mass stool examination and mass treatment for decreasing intestinal helminth and protozoan infection rates in bolivian children: A cross-sectional study. PLoS Negl Trop Dis 2016; 10: e0005147.
25. Rossignol JF, Lopez-Chegne N, Julcamoro LM, Carrion ME, Bardin MC. Nitazoxanide for the empiric treatment of pediatric infectious diarrhea. Trans R Soc Trop Med Hyg 2012; 106: 167-73.
26. Cedillo-Rivera R, Chavez B, Gonzalez-Robles A, Tapia A, Yepez-Mulia L. In vitro effect of nitazoxanide against Entamoeba histolytica, Giardia intestinalis and Trichomonas vaginalis trophozoites. J Eukaryot Microbiol 2002; 49: 201-8.
27. Adagu IS, Nolder D, Warhurst DC, Rossignol JF. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J Antimicrob Chemother 2002; 49: 103-11.
28. Abboud P, Lemee V, Gargala G, et al. Successful treatment of metronidazole and albendazole-resistant giardiasis with nitazoxanide in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2001; 32: 1792-4.
29. Galeh TM, Kazemi A, Mahami-Oskouei M, et al. Introducing nitazoxanide as a promising alternative treatment for symptomatic to metronidazole-resistant giardiasis in clinical isolates. Asian Pac J Trop Med 2016; 9: 887-92.
30. Dunne RL, Dunn LA, Upcroft P, O’Donoghue PJ, Upcroft JA. Drug resistance in the sexually transmitted protozoan Trichomonas vaginalis. Cell Res 2003; 13: 239-49.
31. Leitsch D, Muller J, Muller N. Evaluation of Giardia lamblia thioredoxin reductase as drug activating enzyme and as drug target. Int J Parasitol Drugs Drug Resist 2016; 6: 148-53.
32. Aqeel Y, Siddiqui R, Farooq M, Khan NA. Anaerobic respiration: In vitro efficacy of nitazoxanide against mitochondriate Acanthamoeba castellanii of the T4 genotype. Exp Parasitol 2015; 157: 170-6.
33. Ansell BR, McConville MJ, Ma’ayeh SY, Dagley MJ, Gasser RB, Svard SG, et al. Drug resistance in Giardia duodenalis. Biotechnol Adv 2015; 33: 888-901.
34. Abdel-Magied AA, Hammouda MM, Mosbah A, El-Henawy AA. In vitro activity of nitazoxanide against some metronidazole-resistant and susceptible Trichomonas vaginalis isolates. J Infect Chemother 2017; 23: 230-33.
35. Rossignol JF, Kabil SM, El-Gohary Y, Younis AM. Nitazoxanide in the treatment of amoebiasis. Trans R Soc Trop Med Hyg 2007; 101: 1025-31.
36. Doumbo O, Rossignol JF, Pichard E, et al. Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Am J Trop Med Hyg 1997; 56: 637-9.
37. Custodio H. Protozoan Parasites. Pediatr Rev 2016; 37: 59-69.
38. Valle-Reyes JS, Melnikov V, Dobrovinskaya O, et al. Antiprotozoal drug nitazoxanide enhances parasitemia, tissue lesions and mortality caused by Trypanosoma cruzi in murine model. Exp Parasitol 2017; 172: 44-50.
39. Palencia A, Liu RJ, Lukarska M, et al. Cryptosporidium and Toxoplasma parasites are inhibited by a benzoxaborole targetingleucyl-tRNA synthetase. Antimicrob Agents Chemother 2016; 60: 5817-27.
40. Gargala G, Baishanbo A, Favennec L, Francois A, Ballet JJ, Rossignol JF. Inhibitory activities of epidermal growth factor receptor tyrosine kinase-targeted dihydroxyisoflavone and trihydroxydeoxybenzoin derivatives on Sarcocystis neurona, Neospora caninum, and Cryptosporidium parvum development. Antimicrob Agents Chemother 2005; 49: 4628-34.
41. Brunet J, Lemoine JP, Pesson B, et al. Ruling out nosocomial transmission of Cryptosporidium in a renal transplantation unit: Case report. BMC Infect Dis 2016; 16: 363.
42. Kumar H, Singh VB, Meena BL, Agrawal J, Beniwal S, Swami T. Pulmonary cryptosporidiosis in an immunocompetent host treated successfully with nitazoxanide. Lung India 2016; 33: 69-71.
43. Farthing MJ. Treatment options for the eradication of intestinal protozoa. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 436-45.
44. Florescu DF, Sandkovsky U. Cryptosporidium infection in solid organ transplantation. World J Transplant 2016; 6: 460-71.
45. Abdou AG, Harba NM, Afifi AF, Elnaidany NF. Assessment of Cryptosporidium parvum infection in immunocompetent and immunocompromised mice and its role in triggering intestinal dysplasia. Int J Infect Dis 2013; 17: e593-600.
46. Faraci M, Cappelli B, Morreale G, et al. Nitazoxanide or CD3+/CD4+ lymphocytes for recovery from severe Cryptosporidium infection after allogeneic bone marrow transplant? Pediatr Transplant 2007; 11: 113-6.
47. Vadlamudi N, Maclin J, Dimmitt RA, Thame KA. Cryptosporidial infection in children with inflammatory bowel disease. J Crohns Colitis 2013; 7: e337-43.
48. Galvan-Ramirez Mde L, Duenas Jimenez JM, Rocio Rodriguez Perez L, Troyo-Sanroman R, Ramirez-Herrera M, Garcia-Iglesias T. Effect of nitaxozanide and pyrimethamine on astrocytes infected by Toxoplasma gondii in vitro. Arch Med Res 2013; 44: 415-21.
49. Esposito M, Stettler R, Moores SL, et al. In vitro efficacies of nitazoxanide and other thiazolides against Neospora caninum tachyzoites reveal antiparasitic activity independent of the nitro group. Antimicrob Agents Chemother 2005; 49: 3715-23.
50. Muller J, Hemphill A. Identification of a host cell target for the thiazolide class of broad-spectrum anti-parasitic drugs. Exp Parasitol 2011; 128: 145-50.
51. Dubey JP, Lindsay DS, Saville WJ, Reed SM, Granstrom DE, Speer CA. A review of Sarcocystis neurona and equine protozoal myeloencephalitis (EPM). Vet Parasitol 2001; 95: 89-131.
52. Gargala G, Le Goff L, Ballet JJ, Favennec L, Stachulski AV, Rossignol JF. In vitro efficacy of nitro-and halogenothiazolide thiadiazolide derivatives against Sarcocystis neurona. Vet Parasitol 2009; 162: 230-5.
53. Mesquita JT, Pinto EG, Taniwaki NN, Galisteo AJ Jr., Tempone AG. Lethal action of the nitrothiazolyl-salicylamide derivative nitazoxanide via induction of oxidative stress in Leishmania (L.) infantum. Acta Trop 2013; 128: 666-73.
54. Zhang R, Shang L, Jin H, et al. In vitro and in vivo antileishmanial efficacy of nitazoxanide against Leishmania donovani. Parasitol Res 2010; 107: 475-9.
55. Leitsch D. Drug resistance in the microaerophilic parasite Giardia lamblia. Curr Trop Med Rep 2015; 2: 128-35.
56. Muller J, Naguleswaran A, Muller N, Hemphill A. Neospora caninum: Functional inhibition of protein disulfide isomerase by the broadspectrum anti-parasitic drug nitazoxanide and other thiazolides. Exp Parasitol 2008; 118: 80-8.
57. Juan JO, Lopez Chegne N, Gargala G, Favennec L. Comparative clinical studies of nitazoxanide, albendazole and praziquantel in the treatment of ascariasis, trichuriasis and hymenolepiasis in children from Peru. Trans R Soc Trop Med Hyg 2002; 96: 193-6.
58. Romero Cabello R, Guerrero LR, Munoz Garcia MR, Geyne Cruz A. Nitazoxanide for the treatment of intestinal protozoan and helminthic infections in Mexico. Trans R Soc Trop Med Hyg 1997; 91: 701-3.
59. Favennec L, Jave Ortiz J, Gargala G, Lopez Chegne N, Ayoub A, Rossignol JF. Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru. Aliment Pharmacol Ther 2003; 17: 265-70.
60. Zumaquero-Rios JL, Sarracent-Perez J, Rojas-Garcia R, et al. Fascioliasis and intestinal parasitoses affecting schoolchildren in Atlixco, Puebla State, Mexico: Epidemiology and treatment with nitazoxanide. PLoS Negl Trop Dis 2013; 7: e2553.
61. Monarrez-Espino J, Perez-Espejo CR, Vazquez-Mendoza G, Balleza-Carreon A, Caballero-Hoyos R. Intervention to prevent intestinal parasitic reinfections among Tarahumara indigenous schoolchildren in northern Mexico. Rev Panam Salud Publica 2011; 30: 196-203.
62. Rao RU, Huang Y, Fischer K, Fischer PU, Weil GJ. Brugia malayi: Effects of nitazoxanide and tizoxanide on adult worms and microfilariae of filarial nematodes. Exp Parasitol 2009; 121: 38-45.
63. Stettler M, Fink R, Walker M, et al. In vitro parasiticidal effect of Nitazoxanide against Echinococcus multilocularis metacestodes. Antimicrob Agents Chemother 2003; 47: 467-74.
64. Liu C, Zhang H, Yin J, Hu W. In vivo and in vitro efficacies of mebendazole, mefloquine and nitazoxanide against cyst echinococcosis. Parasitol Res 2015; 114: 2213-22.
65. Stadelmann B, Scholl S, Muller J, Hemphill A. Application of an in vitro drug screening assay based on the release of phosphoglucose isomerase to determine the structure-activity relationship of thiazolides against Echinococcus multilocularis metacestodes. J Antimicrob Chemother 2010; 65: 512-9.
66. Perez-Molina JA, Diaz-Menendez M, Gallego JI, et al. Evaluation of nitazoxanide for the treatment of disseminated cystic echinococcosis: Report of five cases and literature review. Am J Trop Med Hyg 2011; 84: 351-6.
67. Winning A, Braslins P, McCarthy JS. Case report: Nitazoxanide for treatment of refractory bony hydatid disease. Am J Trop Med Hyg 2009; 80: 176-8.
68. Muller J, Sidler D, Nachbur U, Wastling J, Brunner T, Hemphill A. Thiazolides inhibit growth and induce glutathione-S-transferase Pi (GSTP1)-dependent cell death in human colon cancer cells. Int J Cancer 2008; 123: 1797-806.
69. Hemphill A, Stadelmann B, Rufener R, Spiliotis M, Boubaker G, Muller J, et al. Treatment of echinococcosis: Albendazole and mebendazole--what else? Parasite 2014; 21: 70.
70. Fernandez V, Chalar C, Martinez C, Musto H, Zaha A, Fernandez C. Echinococcus granulosus: Molecular cloning and phylogenetic analysis of an inducible glutathione S-transferase. Exp Parasitol 2000; 96: 190-4.
71. Isac E, de APG, da Costa TL, et al. Nitazoxanide induces in vitro metabolic acidosis in Taenia crassiceps cysticerci. Exp Parasitol 2016; 171: 17-22.
72. Somvanshi VS, Ellis BL, Hu Y, Aroian RV. Nitazoxanide: Nematicidal mode of action and drug combination studies. Mol Biochem Parasitol 2014; 193: 1-8.
73. Mkupasi EM, Sikasunge CS, Ngowi HA, Johansen MV. Efficacy and safety of anthelmintics tested against Taenia solium cysticercosis in pigs. PLoS Negl Trop Dis 2013; 7: e2200.
74. Mahanty S, Madrid EM, Nash TE. Quantitative screening for anticestode drugs based on changes in baseline enzyme secretion by Taenia crassiceps. Antimicrob Agents Chemother 2013; 57: 990-5.
75. Palomares-Alonso F, Piliado JC, Palencia G, Ortiz-Plata A, Jung-Cook H. Efficacy of nitazoxanide, tizoxanide and tizoxanide/albendazole sulphoxide combination against Taenia crassiceps cysts. J Antimicrob Chemother 2007; 59: 212-8.
76. Lateef M, Zargar SA, Khan AR, Nazir M, Shoukat A. Successful treatment of niclosamide-and praziquantel-resistant beef tapeworm infection with nitazoxanide. Int J Infect Dis 2008; 12: 80-2.
77. Ashour DS, Abou Rayia DM, Saad AE, El-Bakary RH. Nitazoxanide anthelmintic activity against the enteral and parenteral phases of trichinellosis in experimentally infected rats. Exp Parasitol 2016; 170: 28-35.
78. Delgado OM, Fernandez G, Silva S, Ramirez O, Romero J, Rodriguez-Morales AJ. Preliminary evidence of nitazoxanide activity on Toxocara canis in a mouse model. Int J Antimicrob Agents 2008; 31: 182-4.
79. Lescano SA, Santos SV, Assis JM, Chieffi PP. Efficacy of nitazoxanide against Toxocara canis: Larval recovery and humoral immune response in experimentally infected mice. Rev Inst Med Trop Sao Paulo 2015; 57: 337-41.
80. Silbereisen A, Tritten L, Keiser J. Exploration of novel in vitro assays to study drugs against Trichuris spp. J Microbiol Methods 2011; 87: 169-75.
81. Tritten L, Silbereisen A, Keiser J. Nitazoxanide: In vitro and in vivo drug effects against Trichuris muris and Ancylostoma ceylanicum, alone or in combination. Int J Parasitol Drugs Drug Resist 2012; 2: 98-105.
82. Wimmersberger D, Tritten L, Keiser J. Development of an in vitro drug sensitivity assay for Trichuris muris first-stage larvae. Parasit Vectors 2013; 6: 42.
83. Speich B, Ame SM, Ali SM, et al. Efficacy and safety of nitazoxanide, albendazole, and nitazoxanide-albendazole against Trichuris trichiura infection: A randomized controlled trial. PLoS Negl Trop Dis 2012; 6: e1685.
84. Megraud F, Occhialini A, Rossignol JF. Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole. Antimicrob Agents Chemother 1998; 42: 2836-40.
85. Kennedy AJ, Bruce AM, Gineste C, et al. Synthesis and antimicrobial evaluation of amixicile-based inhibitors of the pyruvate-ferredoxin oxidoreductases of anaerobic bacteria and epsilonproteobacteria. Antimicrob Agents Chemother 2016; 60: 3980-7.
86. de Carvalho LP, Darby CM, Rhee KY, Nathan C. Nitazoxanide disrupts membrane potential and intrabacterial ph homeostasis of Mycobacterium tuberculosis. ACS Med Chem lett 2011; 2: 849-54.
87. Jeankumar VU, Chandran M, Samala G, et al. Development of 5-nitrothiazole derivatives: Identification of leads against both replicative and latent Mycobacterium tuberculosis. Bioorg Med Chem Lett 2012; 22: 7414-7.
88. Gupta A, Tulsankar SL, Bhatta RS, Misra A. Pharmacokinetics, metabolism, and partial biodistribution of "pincer therapeutic" Nitazoxanide in mice following pulmonary delivery of inhalable particles. Mol Pharm 2017; 14(4): 1204-11.
89. Harausz EP, Chervenak KA, Good CE, et al. Activity of nitazoxanide and tizoxanide against Mycobacterium tuberculosis in vitro and in whole blood culture. Tuberculosis (Edinb) 2016; 98: 92-6.
90. Lam KK, Zheng X, Forestieri R, et al. Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis. PLoS Pathog 2012; 8: e1002691.
91. Gupta A, Meena J, Sharma D, et al. Inhalable particles for “pincer therapeutics” targeting nitazoxanide as bactericidal and host-directed agent to macrophages in a mouse model of tuberculosis. Mol Pharm 2016; 13: 3247-55.
92. de Carvalho LP, Lin G, Jiang X, Nathan C. Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance. J Med Chem 2009; 52: 5789-92.
93. Zhang H, Liu X, Yang Y, Li J. Quantitative structure-activity relationship (QSAR) studies on nitazoxanide-based analogues against Clostridium difficile In vitro. Pak J Pharm Sci 2016; 29: 1681-9.
94. Mathur H, Rea MC, Cotter PD, Hill C, Ross RP. The efficacy of thuricin CD, tigecycline, vancomycin, teicoplanin, rifampicin and nitazoxanide, independently and in paired combinations against Clostridium difficile biofilms and planktonic cells. Gut Pathog 2016; 8: 20.
95. Gau JS, Lin WP, Kuo LC, Hu MK. Nitazoxanide analogues as antimicrobial agents against nosocomial pathogens. Med Chem 2016; 12: 544-52.
96. Abd-Elsalam S, Kobtan A, El-Kalla F, et al. A 2-week Nitazoxanidebased quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience. Medicine. 2016; 95: e3879.
97. Baradaran Moghaddam A, Alebouyeh M, Farzi N, Bayati S, Amirmozafari N. Sensitivity to nitazoxanide among metronidazole resistant Helicobacter pylori strains in patients with gastritis. Med J Islam Repub Iran 2016; 30: 405.
98. Ramos-Soriano AG, Black J. Nitazoxanide use as part of an empiric multi-drug regimen in treating children with suspected Helicobacter pylori infection. Case Rep Gastroenterol 2015; 9: 36-42.
99. Shamir ER, Warthan M, Brown SP, Nataro JP, Guerrant RL, Hoffman PS. Nitazoxanide inhibits biofilm production and hemagglutination by enteroaggregative Escherichia coli strains by blocking assembly of AafA fimbriae. Antimicrob Agents Chemother 2010; 54: 1526-33.
100. Pankuch GA, Appelbaum PC. Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic species. Antimicrob Agents Chemother 2006; 50: 1112-7.
101. Bolick DT, Roche JK, Hontecillas R, Bassaganya-Riera J, Nataro JP, Guerrant RL. Enteroaggregative Escherichia coli strain in a novel weaned mouse model: Exacerbation by malnutrition, biofilm as a virulence factor and treatment by nitazoxanide. J Med Microbiol 2013; 62: 896-905.
102. Chahales P, Hoffman PS, Thanassi DG. Nitazoxanide inhibits pilus biogenesis by interfering with folding of the usher protein in the outer membrane. Antimicrob Agents Chemother 2016; 60: 2028-38.
103. Stachulski AV, Pidathala C, Row EC, et al. Thiazolides as novel antiviral agents. 2. Inhibition of hepatitis C virus replication. J Med Chem 2011; 54: 8670-80.
104. Stachulski AV, Pidathala C, Row EC, et al. Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication. Med Chem 2011; 54: 4119-32.
105. Rossignol JF, La Frazia S, Chiappa L, Ciucci A, Santoro MG. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem 2009; 284: 29798-808.
106. Koszalka P, Tilmanis D, Hurt AC. Influenza antivirals currently in late-phase clinical trial. Influenza Other Respir Viruses 2017; 11(3): 240-6.
107. Zeng LY, Yang J, Liu S. Investigational hemagglutinin-targeted influenza virus inhibitors. Expert Opin Investig Drugs 2017; 26: 63-73.
108. Rossignol JF. Nitazoxanide: A first-in-class broad-spectrum antiviral agent. Antiviral Res 2014; 110: 94-103.
109. Belardo G, Cenciarelli O, La Frazia S, Rossignol JF, Santoro MG. Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza a viruses in vitro. Antimicrob Agents Chemother 2015; 59: 1061-9.
110. Song JY, Noh JY, Choi WS, Cheong HJ, Kim WJ. Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives. Expert Rev Anti Infect Ther 2015; 13: 1361-72.
111. Kratky M, Vinšova J. Antiviral activity of substituted salicylanilides -a review. Mini-Reviews in Medicinal Chemistry 2011; 11: 956-67.
112. Rossignol JF. Thiazolides: A new class of antiviral drugs. Expert Opin Drug Metab Toxicol 2009; 5: 667-74.
113. Kohla MA, El-Said H, El-Fert A, Ehsan N, Ezzat S, Taha H. Impact of nitazoxanide on sustained virologic response in Egyptian patients with chronic hepatitis C genotype 4: A double-blind placebo-controlled trial. Eur J Gastroenterol Hepatol 2016; 28: 42-7.
114. Siddiq DM, Koo HL, Adachi JA, Viola GM. Norovirus gastroenteritis successfully treated with nitazoxanide. J Infect 2011; 63: 394-7.
115. Woodward J, Gkrania-Klotsas E, Kumararatne D. Chronic norovirus infection and common variable immunodeficiency. Clin Exp Immunol 2016; 188(3): 363-70.
116. Elazar M, Liu M, McKenna SA, et al. The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. Gastroenterol 2009; 137: 1827-35.
117. Ashiru O, Howe JD, Butters TD. Nitazoxanide, an antiviral thiazolide, depletes ATP-sensitive intracellular Ca(2+) stores. Virology 2014; 462: 135-48.
118. Petersen T, Lee YJ, Osinusi A, et al. Interferon-stimulated gene expression in HIV/HCV coinfected patients treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin. AIDS Res Hum Retroviruses 2016; 32: 660-7.
119. Debing Y, Neyts J, Delang L. The future of antivirals: Broad-spectrum inhibitors. Curr Opin Infect Dis 2015; 28: 596-602.
120. Mercorelli B, Luganini A, Nannetti G, et al. Drug repurposing approach identifies inhibitors of the prototypic viral transcription factor IE2 that block human cytomegalovirus replication. Cell Chem Biol 2016; 23: 340-51.
121. Wang YM, Lu JW, Lin CC, et al. Antiviral activities of niclosamide and nitazoxanide against chikungunya virus entry and transmission. Antiviral Res 2016; 135: 81-90.
122. Rossignol JF. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health 2016; 9: 227-30.
123. Gekonge B, Bardin MC, Montaner LJ. Short communication: Nitazoxanide inhibits HIV viral replication in monocyte-derived macrophages. AIDS Res Hum Retroviruses 2015; 31: 237-41.
124. Trabattoni D, Gnudi F, Ibba SV, et al. Thiazolides elicit anti-viral innate immunity and reduce HIV replication. Sci Rep 2016; 6: 27148.
125. Di Santo N, Ehrisman J. A functional perspective of nitazoxanide as a potential anticancer drug. Mutat Res 2014; 768: 16-21.
126. Fan-Minogue H, Bodapati S, Solow-Cordero D, et al. A c-Myc activation sensor-based high-throughput drug screening identifies an antineoplastic effect of nitazoxanide. Mol Cancer Ther 2013; 12:1896-905
127. Chahales P, Hoffman PS, Thanassi DG. Nitazoxanide inhibits pilus biogenesis by interfering with folding of the usher protein in the outer membrane. Antimicrob Agents Chemother 2016; 60: 2028-38.
128. Stachulski AV, Pidathala C, Row EC, et al. Thiazolides as novel antiviral agents. 2. Inhibition of hepatitis C virus replication. J Med Chem 2011; 54: 8670-80.
129. Stachulski AV, Pidathala C, Row EC, et al. Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication. Med Chem 2011; 54: 4119-32.
130. Rossignol JF, La Frazia S, Chiappa L, Ciucci A, Santoro MG. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem 2009; 284: 29798-808.
131. Koszalka P, Tilmanis D, Hurt AC. Influenza antivirals currently in late-phase clinical trial. Influenza Other Respir Viruses 2017; 11(3): 240-6.
132. Zeng LY, Yang J, Liu S. Investigational hemagglutinin-targeted influenza virus inhibitors. Expert Opin Investig Drugs 2017; 26: 63-73.
133. Rossignol JF. Nitazoxanide: A first-in-class broad-spectrum antiviral agent. Antiviral Res 2014; 110: 94-103.
134. Belardo G, Cenciarelli O, La Frazia S, Rossignol JF, Santoro MG. Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza a viruses in vitro. Antimicrob Agents Chemother 2015; 59: 1061-9.
135. Song JY, Noh JY, Choi WS, Cheong HJ, Kim WJ. Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives. Expert Rev Anti Infect Ther 2015; 13: 1361-72.
136. Kratky M, Vinšova J. Antiviral activity of substituted salicylanilides -a review. Mini-Reviews in Medicinal Chemistry 2011; 11: 956-67.
137. Rossignol JF. Thiazolides: A new class of antiviral drugs. Expert Opin Drug Metab Toxicol 2009; 5: 667-74.
138. Kohla MA, El-Said H, El-Fert A, Ehsan N, Ezzat S, Taha H. Impact of nitazoxanide on sustained virologic response in Egyptian patients with chronic hepatitis C genotype 4: A double-blind placebo-controlled trial. Eur J Gastroenterol Hepatol 2016; 28: 42-7.
139. Siddiq DM, Koo HL, Adachi JA, Viola GM. Norovirus gastroenteritis successfully treated with nitazoxanide. J Infect 2011; 63: 394-7.
140. Woodward J, Gkrania-Klotsas E, Kumararatne D. Chronic norovirus infection and common variable immunodeficiency. Clin Exp Immunol 2016; 188(3): 363-70.
141. Elazar M, Liu M, McKenna SA, et al. The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. Gastroenterol 2009; 137: 1827-35.
142. Ashiru O, Howe JD, Butters TD. Nitazoxanide, an antiviral thiazolide, depletes ATP-sensitive intracellular Ca(2+) stores. Virology 2014; 462: 135-48.
143. Petersen T, Lee YJ, Osinusi A, et al. Interferon-stimulated gene expression in HIV/HCV coinfected patients treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin. AIDS Res Hum Retroviruses 2016; 32: 660-7.
144. Debing Y, Neyts J, Delang L. The future of antivirals: Broad-spectrum inhibitors. Curr Opin Infect Dis 2015; 28: 596-602.
145. Mercorelli B, Luganini A, Nannetti G, et al. Drug repurposing approach identifies inhibitors of the prototypic viral transcription factor IE2 that block human cytomegalovirus replication. Cell Chem Biol 2016; 23: 340-51.
146. Wang YM, Lu JW, Lin CC, et al. Antiviral activities of niclosamide and nitazoxanide against chikungunya virus entry and transmission. Antiviral Res 2016; 135: 81-90.
147. Rossignol JF. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health 2016; 9: 227-30.
148. Gekonge B, Bardin MC, Montaner LJ. Short communication: Nitazoxanide inhibits HIV viral replication in monocyte-derived macrophages. AIDS Res Hum Retroviruses 2015; 31: 237-41.
149. Trabattoni D, Gnudi F, Ibba SV, et al. Thiazolides elicit anti-viral innate immunity and reduce HIV replication. Sci Rep 2016; 6: 27148.
150. Di Santo N, Ehrisman J. A functional perspective of nitazoxanide as a potential anticancer drug. Mutat Res 2014; 768: 16-21.
151. Fan-Minogue H, Bodapati S, Solow-Cordero D, et al. A c-Myc activation sensor-based high-throughput drug screening identifies anthe arylimidamide DB750 and the thiazolide nitazoxanide. Exp Parasitol 2011; 129: 95-100.
152. Rossignol JF, Abaza H, Friedman H. Successful treatment of human fascioliasis with nitazoxanide. Trans R Soc Trop Med Hyg 1998; 92: 103-4.
153. Chero JC, Saito M, Bustos JA, Blanco EM, Gonzalvez G, Garcia HH. Hymenolepis nana infection: Symptoms and response to nitazoxanide in field conditions. Trans R Soc Trop Med Hyg 2007; 101: 203-5.
154. Walker M, Rossignol JF, Torgerson P, Hemphill A. In vitro effects of nitazoxanide on Echinococcus granulosus protoscoleces and metacestodes. J Antimicrob Chemother 2004; 54: 609-16.
155. Gavidia CM, Gonzalez AE, Lopera L, et al. Evaluation of nitazoxanide and oxfendazole efficacy against cystic echinococcosis in naturally infected sheep. Am J Trop Med Hyg 2009; 80: 367-72.
156. Reuter S, Manfras B, Merkle M, Harter G, Kern P. In vitro activities of itraconazole, methiazole, and nitazoxanide versus Echinococcus multilocularis larvae. Antimicrob Agents Chemother 2006; 50: 2966-70.
157. Stettler M, Rossignol JF, Fink R, et al. Secondary and primary murine alveolar echinococcosis: Combined albendazole/nitazoxanide chemotherapy exhibits profound anti-parasitic activity. Int J Parasitol 2004; 34: 615-24.
158. Laura C, Celina E, Sergio SB, Guillermo D, Carlos L, Luis A. Combined flubendazole-nitazoxanide treatment of cystic echinococcosis: Pharmacokinetic and efficacy assessment in mice. Acta Trop 2015; 148: 89-96.
159. Galvan-Ramirez ML, Rivera N, Loeza ME, et al. Nitazoxanide in the treatment of Ascaris lumbricoides in a rural zone of Colima, Mexico. J Helminthol 2007; 81: 255-9.
160. Diaz E, Mondragon J, Ramirez E, Bernal R. Epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico. Am J Trop Med Hyg 2003; 68: 384-5.
161. Hu Y, Ellis BL, Yiu YY, et al. An extensive comparison of the effect of anthelmintic classes on diverse nematodes. PloS One 2013; 8: e70702.
162. Fonseca-Salamanca F, Martinez-Grueiro MM, Martinez-Fernandez AR. Nematocidal activity of nitazoxanide in laboratory models. Parasitol Res 2003; 91: 321-4.
163. Geary TG, Sangster NC, Thompson DP. Frontiers in anthelmintic pharmacology. Vet Parasitol 1999; 84: 275-95.
164. Dalia S, Colvin GA. Eosinophilia secondary to strongyloides in Rhode Island. Med Health R I 2010; 93: 92-3.
165. Bobak DA. Nitazoxanide to treat persistent Clostridium difficile colitis. Curr Infect Dis Rep 2008; 10: 89-91.
166. Dubreuil L, Houcke I, Mouton Y, Rossignol JF. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob Agents Chemother 1996; 40: 2266-70.
167. Freeman J, Baines SD, Todhunter SL, Huscroft GS, Wilcox MH. Nitazoxanide is active against Clostridium difficile strains with reduced susceptibility to metronidazole. J Antimicrob Chemother 2011; 66: 1407-8.
168. McVay CS, Rolfe RD. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob Agents Chemother 2000; 44: 2254-8.
169. Musher DM, Logan N, Bressler AM, Johnson DP, Rossignol JF. Nitazoxanide versus vancomycin in Clostridium difficile infection: A randomized, double-blind study. Clin Infect Dis 2009; 48: e41-6.
170. Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficilecolitis. Clin Infect Dis 2006; 43: 421-7.
171. Rafiullah F, Kanwal S, Majeed UM, et al. Successful use of nitazoxanide in the treatment of recurrent Clostridium difficile infection. BMJ Case Rep 2011; 2011: bcr0420114123.
172. Yangco BG, Sher G, Bardin MC. Nitazoxanide and probiotics for the treatment of recurrent Clostridium difficile infection in a peritoneal dialysis patient. South Med J 2009; 102: 746-7.
173. Young JD, Mangino JE, Stevenson KB, Koletar SL. Nitazoxanide versus metronidazole for Clostridium difficile-associated colitis. Clin Infect Dis 2007; 44: 152.
174. Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, Flynn M. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol 2011; 106: 1970-5.
175. Guttner Y, Windsor HM, Viiala CH, Dusci L, Marshall BJ. Nitazoxanide in treatment of Helicobacter pylori: A clinical and in vitro study. Antimicrob Agents Chemother 2003; 47: 3780-3.
176. Megraud F, Occhialini A, Rossignol JF. Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole. Antimicrob Agents Chemother 1998; 42: 2836-40.
177. St Maurice M, Cremades N, Croxen MA, Sisson G, Sancho J, Hoffman PS. Flavodoxin:quinone reductase (FqrB): A redox partner of pyruvate:ferredoxin oxidoreductase that reversibly couples pyruvate oxidation to NADPH production in Helicobacter pylori and Campylobacter jejuni. J Bacteriol 2007; 189: 4764-73.
178. Yamamoto Y, Hakki A, Friedman H, et al. Nitazoxanide, a nitrothiazolide antiparasitic drug, is an anti-Helicobacter pylori agent with anti-vacuolating toxin activity. Chemother 1999; 45: 303-12.
179. Iacobino A, Piccaro G, Giannoni F, Mustazzolu A, Fattorini L. Activity of drugs against dormant Mycobacterium tuberculosis. Int J Mycobacteriol 2016;5: S94-S5.
180. Piccaro G, Giannoni F, Filippini P, Mustazzolu A, Fattorini L. Activities of drug combinations against Mycobacterium tuberculosis grown in aerobic and hypoxic acidic conditions. Antimicrob Agents Chemother 2013; 57: 1428-33.
181. Shigyo K, Ocheretina O, Merveille YM, et al. Efficacy of nitazoxanide against clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2013; 57: 2834-7.
182. Nikolova K, Gluud C, Grevstad B, Jakobsen JC. Nitazoxanide for chronic hepatitis C. Cochrane Database Syst Rev 2014; 4: CD009182.
183. Keeffe EB, Rossignol JF. Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides. World J Gastroenterol 2009; 15: 1805-8.
184. Korba BE, Elazar M, Lui P, Rossignol JF, Glenn JS. Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob Agents Chemother 2008; 52: 4069-71.
185. Korba BE, Montero AB, Farrar K, et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res 2008; 77: 56-63.
186. Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterol 2009; 136: 856-62.
187. Rossignol JF, Kabil SM, El-Gohary Y, Elfert A, Keeffe EB. Clinical trial: Randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2008; 28: 574-80.
188. Rossignol JF, Keeffe EB. Thiazolides: A new class of drugs for the treatment of chronic hepatitis B and C. Future Microbiol 2008; 3: 539-45.
189. Yon C, Viswanathan P, Rossignol JF, Korba B. Mutations in HCV non-structural genes do not contribute to resistance to nitazoxanide in replicon-containing cells. Antiviral Res 2011; 91: 233-40.
190. Ashton LV, Callan RL, Rao S, Landolt GA. In vitro susceptibility of canine Influenza A (H3N8) virus to Nitazoxanide and Tizoxanide. Vet Med Int 2010; 2010: 891010.
191. Haffizulla J, Hartman A, Hoppers M, et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: A doubleblind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis 2014; 14: 609-18.
192. Taubel J, Lorch U, Rossignol JF, Ferber G, Camm AJ. Analyzing the relationship of QT interval and exposure to nitazoxanide, a prospective candidate for influenza antiviral therapy--A formal TQT study. J Clin Pharmacol 2014; 54: 987-94.
193. Shi Z, Wei J, Deng X, et al. Nitazoxanide inhibits the replication of Japanese encephalitis virus in cultured cells and in a mouse model. Virol J 2014; 11: 10.
194. Bekerman E, Einav S. Combating emerging viral threats: Broadspectrum antiviral drugs are under development to treat emerging viral diseases such as Ebola and dengue for which no specific, licensed treatments exist. Science. 2015; 348: 282-3.
195. Lee PJ, Krilov LR. Germs on a plane -Infectious issues and the pediatric international traveler: What pediatricians should know. Pediatr Ann 2007; 36: 344-51.
196. Pastorino B, Nougairede A, Wurtz N, Gould E, de Lamballerie X. Role of host cell factors in flavivirus infection: Implications for pathogenesis and development of antiviral drugs. Antiviral Res 2010; 87: 281-94.
197. Brown LK, Clark I, Brown JR, Breuer J, Lowe DM. Norovirus infection in primary immune deficiency. Rev Med Virol 2017 (In press).
198. Rossignol JF, El-Gohary YM. Nitazoxanide in the treatment of viral gastroenteritis: A randomized double-blind placebo-controlled clinical trial. Aliment Pharmacol Ther 2006; 24: 1423-30.
199. De Graaf M, Van Beek J, Koopmans MPG. Human norovirus transmission and evolution in a changing world. Nat Rev Microbiol 2016; 14: 421-33.
200. La Frazia S, Ciucci A, Arnoldi F, et al. Thiazolides, a new class of antiviral agents effective against rotavirus infection, target viral morphogenesis, inhibiting viroplasm formation. J Virol 2013; 87: 11096-106.
201. Rossignol JF, Abu-Zekry M, Hussein A, Santoro MG. Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: Randomised double-blind placebo-controlled trial. Lancet 2006; 368: 124-9.
202. Hayden FG. Advances in antivirals for non-influenza respiratory virus infections. Influenza Other Respir Viruses 2013; 7: 36-43.
203. Cao J, Forrest JC, Zhang X. A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs. Antiviral Res 2015; 114: 1-10.